ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma

Clinical Chemistry

Volumn 53, Issue 2, 2007, Pages 241-250

  Cho, William C S ^a   Yip, Timothy T C ^a   Ngan, Roger K C ^a   Yip, Tai Tung ^b   Podust, Vladimir N ^b   Yip, Christine ^b   Yiu, Harry H Y ^a   Yip, Victor ^b   Cheng, Wai Wai ^a   Ma, Victor W S ^a   Law, Stephen C K ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; CISPLATIN; ETOPOSIDE; GEMCITABINE; INTER ALPHA TRYPSIN INHIBITOR; THROMBOCYTE FACTOR 4;

ADULT; AGED; ANTIBODY AFFINITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA FINGERPRINTING; FEMALE; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PHASE 2 CLINICAL TRIAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; SALVAGE THERAPY; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE;

ADULT; ALPHA-GLOBULINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PLATELET FACTOR 4; PROTEIN ARRAY ANALYSIS; PROTEIN PRECURSORS; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 33846706710     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.065805     Document Type: Article

References (39)

1. Hong Kong cancer statistics 2000. Hong Kong Hospital Authority Cancer Registry Annual Bulletin 2005; 5.
2. Lee AW, Poon YF, Foo W, Law SCK, Cheung FK, Chan DK, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-85: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261-70.
3. Lee AW, Sze WM, Au JSK, Leung SF, Leung TW, Chua DT, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005;61:1107-16.
4. Leung SF, Teo PM, Shiu WW, Tsao SY, Leung TW. Clinical features and management of distant metastases of nasopharyngeal carcinoma. J Otolaryngol 1991;20:27-9.
5. Hsu CH, Chen CL, Hong RL, Chen KL, Lin JF, Cheng AL. Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy. Oncology 2002;62:305-12.
6. Cho WCS, Yip TTC, Yip C, Yip V, Thulasiraman V, Ngan RKC, et al. identification of Serum Amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10:43-52.
7. Yiu HHY, Ngan RKC, Yau S, Cheung FY, Chan DTM, Kwok PCH, et al. Interim results of a phase II study on combination cisplatin and etoposide chemotherapy for metastatic or recurrent nasopharyngeal carcinoma (NPC). Proc Am Soc Clin Oncol 2003;22:511 [Abstr No. 2056].
8. Ngan RKC, Yiu HHY, Lau WH, Yau S, Cheung FY, Chan DTM, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a Phase II study. Ann Oncol 2002;13:1252-8.
9. Yip TTC, Cho WCS, Cheng WW, Chan JWM, Ma VWS, Yip TT, et al. Application of protein chip array profiling in serum biomarker discovery for patients suffering from severe acute respiratory syndrome (SARS). In: Rampal JB, ed. Microarray: Methods and Protocols. Method in Molecular Biology Series. U S A: Humana Press [In press].
10. Yip TT, Lomas L. SELDI ProteinChip array in oncoproteomic research. Technol Cancer Res Treat 2002;1:273-80.
11. Loh WY, Shih YS. Split selection methods for classification trees. Statistica Sinica 1997;7:815-40.
12. Vermeulen R, Lan Q, Zhang L, Gunn L, McCarthy D, Woodbury RL, et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers. PNAS U S A 2005;102:17041-6.
13. Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ, Koong AC. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004;10:4806-12.
14. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004;10:1625-32.
15. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005;51:2236-44.
16. Leung SF, Tam JS, Chan AT, Zee B, Chan LY, Huang DP, et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004;50:339-45.
17. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
18. Ngan RKC, Lau WH, Yip TTC, Cho WCS, Cheng WW, Lim CKP, et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann N Y Acad Sci 2001;945:73-9.
19. Josic D, Brown MK, Huang F, Lim YP, Rucevic M, Clifton JG, et al. Proteomic characterization of inter-α inhibitor proteins from human plasma. Proteomics 2006;6:2874-85.
20. Heron A, Borghi H, Calle A, Bourguignon J, Diarra-Mehrpour M, Martin JP, et al. Gene expression and protein distribution of inter-α-trypsin inhibitor in three human hepatoma cell lines. Cell Biol Int 1995;19:593-602.
21. Bourguignon J, Borghi H, Sesboue R, Diarra-Mehrpour M, Bernaudin JF, Metayer J, et al. Immunohistochemical distribution of inter-α-trypsin inhibitor chains in normal and malignant human lung tissue. J Histochem Cytochem 1999;47:1625-32.
22. Yoshida E, Maruyama M, Sugiki M, Mihara H. Immunohistochemical demonstration of bikunin, a light chain of inter-α-trypsin inhibitor, in human brain tumors. Inflammation 1994;18:589-96.
23. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
24. Yu KH, Rustgi AK, Blair IA. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005;4:1742-51.
25. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005;115:783-9.
26. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84.
27. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
28. Wilharm E, Parry MA, Friebel R, Tschesche H, Matschiner G, Sommerhoff CP, et al. Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. J Biol Chem 1999;274:27331-7.
29. Slungaard A. Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol 2005;37:1162-7.
30. Al-Mondhiry H, Manni A, Owen J, Gordon R. Hemostatic effects of hormonal stimulation in patients with metastatic prostate cancer. Am J Hematol 1988;28:141-5.
31. Palomera Bernal L, Garcia Diez I. Beta-thromboglobulin and platelet factor 4 in a follow-up of acute myelofibrosis (megakaryoblastic leukemia) Med Clin (Barc) 1990;95:21-4.
32. Al-Mondhiry H. beta-Thromboglobulin and platelet-factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy. Am J Hematol 1983;14:105-11.
33. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006;52:1223-37.
34. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20:6597-606.
35. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res 1997;3:1195-200.
36. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:77-85.
37. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-12.
38. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005;5:3262-77.
39. Banks RE, Stanley AJ, Caims DA, Barrett JH, Clarke P, Thompson D, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51:1637-49.